Market Cap | 7.40M | P/E | - | EPS this Y | 12.50% | Ern Qtrly Grth | - |
Income | -5.73M | Forward P/E | -1.55 | EPS next Y | 21.60% | 50D Avg Chg | - |
Sales | 17k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 1.00% |
Dividend | N/A | Price/Book | 0.50 | EPS next 5Y | - | 52W High Chg | -63.00% |
Recommedations | 2.00 | Quick Ratio | 19.86 | Shares Outstanding | 1.34M | 52W Low Chg | 59.00% |
Insider Own | 2.75% | ROA | -34.27% | Shares Float | 1.30M | Beta | 5.04 |
Inst Own | 5.18% | ROE | -53.71% | Shares Shorted/Prior | 9.51K/18.09K | Price | 5.26 |
Gross Margin | 60.00% | Profit Margin | - | Avg. Volume | 82,529 | Target Price | - |
Oper. Margin | -20,316.32% | Earnings Date | Nov 12 | Volume | 28,407 | Change | -5.73% |
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Warbington Timothy | President & CEO President & CEO | Jun 27 | Buy | 4.42 | 1,000 | 4,420 | 12,209 | 06/29/23 |
Warbington Timothy | President & CEO President & CEO | Nov 21 | Buy | 0.39 | 25,000 | 9,750 | 112,087 | 11/23/22 |
Finger Michael H. | Director Director | Sep 27 | Buy | 0.50 | 2,000 | 1,000 | 18,502 | 09/29/22 |
Warbington Timothy | President & CEO President & CEO | Sep 27 | Buy | 0.50 | 20,000 | 10,000 | 87,087 | 09/28/22 |
Warbington Timothy | President & CEO President & CEO | Sep 21 | Buy | 0.6 | 42,000 | 25,200 | 67,087 | 09/22/22 |
Finger Michael H. | Director Director | Jun 14 | Buy | 0.70 | 10,000 | 7,000 | 16,502 | 06/14/22 |
Finger Michael H. | Director Director | May 20 | Buy | 1.50 | 6,500 | 9,750 | 6,502 | 05/20/22 |